Mounjaro: what type of drug is it, and how does that shape what it does?

What drug class does Mounjaro belong to?

Mounjaro belongs to a class called incretin mimetics, medicines that replicate the action of hormones the gut naturally releases after eating. More precisely, it is a dual GIP and GLP-1 receptor agonist. GIP stands for glucose-dependent insulinotropic polypeptide; GLP-1 stands for glucagon-like peptide-1. Both are incretin hormones. In people with obesity, the signalling from these hormones is often blunted, and Mounjaro is designed to restore and amplify it.

What sets Mounjaro apart from older medicines in the same broad family is that it activates both receptors rather than one. Semaglutide, for example, targets only the GLP-1 receptor. Tirzepatide (the drug name behind the Mounjaro brand) was engineered to combine both actions in a single molecule, which is why it is sometimes described as the first of a new sub-class within the incretin family.

The NHS patient information for tirzepatide describes its action as reducing appetite and slowing gastric emptying, resulting in a lower calorie intake over time. This is worth reading before any consultation, as it covers what the medicine does and what to expect from it.

How does the dual-agonist mechanism actually work day to day?

After you inject Mounjaro once a week, tirzepatide circulates and binds to GIP and GLP-1 receptors in the brain, gut and pancreas. The combined effect is a meaningful reduction in appetite, most people find they feel full sooner and stay full for longer. Gastric emptying slows, so food passes through the stomach more gradually, which also moderates blood-glucose rises after meals.

None of this involves stimulants, appetite suppressants of the amphetamine family, or fat-blocking. The mechanism is hormonal. That distinction matters because the side-effect profile and the way the body adapts to the medicine are quite different from older weight-loss drugs. Understanding how tirzepatide works at a pharmacological level can help people set realistic expectations before treatment starts.

Treatment begins at 2.5 mg (a dose chosen for tolerability while the body adjusts) and is titrated upward by the prescriber over several weeks. The goal is to reach the dose that produces meaningful weight reduction with manageable side effects for that individual. The prescriber, not the patient, sets that pace based on clinical review.

Is Mounjaro a diabetes drug, a weight-loss drug, or both?

Both, depending on the licensed indication. If you want a fuller picture of what kind of drug Mounjaro is and how it is classified, it holds two distinct UK licences: one for weight management in adults meeting the BMI criteria described in the SmPC, and one for type 2 diabetes. The drug itself is the same; the indication, the prescribing pathway and the clinical context differ. This is not unusual, several medicines carry multiple licences for related conditions.

For the purposes of weight management, Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition (such as hypertension, dyslipidaemia or obstructive sleep apnoea) is present. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. NICE's appraisal of tirzepatide for weight management, TA1026, provides the detailed eligibility framework that NHS prescribers follow.

If you are weighing up which medicine might suit your situation, a useful starting point is our overview of weight-loss treatment options, which sets out what is currently licensed and available in the UK. The question of whether Mounjaro or another medicine is right for you, though, is always answered by a prescriber after reviewing your health history, not by a webpage.

What does the Black Triangle designation mean for patients?

Every Mounjaro pen carries a small black inverted triangle (▼) in its labelling. This is an MHRA designation applied to medicines that are newly licensed or that the regulator wants to monitor more closely as real-world data builds. It does not mean the medicine is considered unsafe, it means that reporting suspected side effects is especially encouraged, and that healthcare professionals and patients should be particularly attentive.

Patients can report any suspected side effect through the MHRA Yellow Card scheme, which accepts reports directly from the public. This kind of post-market reporting is how the safety picture of newer medicines gets refined over time, it is a normal and important part of how drug regulation works in the UK, not a reason for alarm.

If you are curious about how Mounjaro's cost compares across private providers before deciding whether to start a consultation, our Mounjaro pricing guide covers what a legitimate private prescription typically involves. When you are ready to take the next step, our clinical team reviews consultations the same day, a real prescriber reads your answers, not software.